IDEXX Laboratories, Inc. (ETR:IX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 47.77B -4.7% |
| Revenue (ttm) | 4.11B +11.9% |
| Net Income | 1.04B +15.1% |
| EPS | 13.31 +17.7% |
| Shares Out | n/a |
| PE Ratio | 45.44 |
| Forward PE | 41.86 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9 |
| Open | 599.20 |
| Previous Close | 600.20 |
| Day's Range | 592.40 - 604.80 |
| 52-Week Range | 431.80 - 663.20 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About IDEXX Laboratories
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides com... [Read more]
Financial Performance
In 2025, IDEXX Laboratories's revenue was $4.30 billion, an increase of 10.42% compared to the previous year's $3.90 billion. Earnings were $1.06 billion, an increase of 19.33%.
Financial numbers in USD Financial StatementsNews
Idexx Laboratories price target raised to $770 from $705 at Jefferies
Jefferies analyst Keith Devas raised the firm’s price target on Idexx Laboratories (IDXX) to $770 from $705 and keeps a Buy rating on the shares. Another quarter of double-digit growth…
Idexx Laboratories price target raised to $810 from $805 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Idexx Laboratories (IDXX) to $810 from $805 and keeps an Overweight rating on the shares.
Idexx Laboratories price target raised to $700 from $627 at UBS
UBS raised the firm’s price target on Idexx Laboratories (IDXX) to $700 from $627 and keeps a Neutral rating on the shares. The company delivered a clean beat-and-raise in Q3…
Idexx Laboratories rises 19.2%
Idexx Laboratories (IDXX) is up 19.2%, or $105.79 to $657.00.
IDEXX raises forecast, betting diagnostics can offset weak vet visits
IDEXX Laboratories beat quarterly estimates and raised its annual profit and revenue forecast on Monday, betting that rising diagnostic use per visit and new product launches will sustain growth thr...
Idexx Laboratories rises 18.6%
Idexx Laboratories (IDXX) is up 18.6%, or $102.29 to $653.50.
IDEXX Laboratories Earnings Call Transcript: Q3 2026
Q3 organic revenue grew 10% and EPS rose 18% reported, driven by diagnostic demand, innovation, and execution. FY2026 revenue and EPS guidance increased, while CoVet adds growth potential and near-term margin dilution.
IDEXX Laboratories Earnings release: Q3 2026
IDEXX Laboratories released its Q3 2026 earnings on November 2, 2026, summarizing the period's financial results.
IDEXX Laboratories Prepared remarks: Q3 2026
IDEXX Laboratories filed a regulatory document on November 2, 2026 disclosing important business information.
IDEXX Laboratories Quarterly report: Q3 2026
IDEXX Laboratories has published its Q3 2026 quarterly earnings report on November 2, 2026.
IDEXX Laboratories Slides: Q3 2026
IDEXX Laboratories has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 2, 2026.
Idexx Laboratories raises FY26 EPS view to $14.96-$15.16 from $14.69-$14.94
2026 EPS consensus $14.88. Raises 2026 revenue view to $4.74B-$4.77B from $4.70B-$4.75B, or reported growth of 10.1%-10.8%, up $32M at midpoint. 2026 revenue consensus $4.72B. Raises outlook for 2026 ...
Idexx Laboratories reports Q3 EPS $4.01 with items, consensus $3.71
Reports Q3 revenue $1.21B, consensus $1.19B. Q3 EPS included 3c per share benefit from a non-operating gain on an equity investment, 1c per share in tax benefits from share-based compensation,…
IDEXX Laboratories Announces Third Quarter Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, today announced third quarter results. Third Quarter Results The Company repor...
Idexx Laboratories price target lowered to $627 from $670 at UBS
UBS lowered the firm’s price target on Idexx Laboratories (IDXX) to $627 from $670 and keeps a Neutral rating on the shares.
Idexx Laboratories price target lowered to $750 from $775 at JPMorgan
JPMorgan lowered the firm’s price target on Idexx Laboratories (IDXX) to $750 from $775 and keeps an Overweight rating on the shares. The firm sees largely inline Q3 results from…
Idexx Laboratories initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Matt Dellatorre initiated coverage of Idexx Laboratories (IDXX) with a Buy rating and $740 price target The firm views the company as a “high-quality compounder” in animal…
Idexx Laboratories initiated with a Sector Weight at KeyBanc
KeyBanc analyst Steve Dechert initiated coverage of Idexx Laboratories (IDXX) with a Sector Weight rating and no price target The firm expects U.S. vet visits to remain soft for at…
IDEXX Laboratories to Release 2026 Third Quarter Financial Results
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Mond...
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories
Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced t...
IDEXX Expands Faecal Dx Antigen Testing Platform in the United Kingdom with Taeniid Tapeworm Detection
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
Idexx Laboratories announces acquisition of CoVetAI
IDEXX Laboratories (IDXX) announced the acquisition of CoVetAI, a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. CoVet hel...
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
IDEXX Laboratories Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Long-term targets remain 10%+ organic growth and 15%+ EPS growth, supported by diagnostic utilization, innovation and commercial investment. 2026 H2 clinical visits are guided down ~1.5%; inVue Dx, Cancer Dx and upcoming launches extend growth opportunities.
IDEXX Laboratories Transcript: Barclays 24th Annual Global Financial Services Conference
Strong Q2 performance and raised guidance reflect robust recurring revenue growth and successful innovation adoption. Aging pet demographics, resilient care demand, and new diagnostic platforms like inVue Dx and Cancer Dx are driving higher utilization and market share. Commercial expansion and AI integration support long-term growth and margin improvement.